ArticleMedical science monitor : international medical journal of experimental and clinical research2018
Martrilin-3 (MATN3) Overexpression in Gastric Adenocarcinoma and its Prognostic Significance.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Article
- A prognostic model for gastric cancer constructed by multiple machine learning algorithms.Journal of molecular histology · 2025Article
- EDC4 enhances multi-drug chemosensitivity in pancreatic cancer via GR50-based profiling.Cancer cell international · 2025Article
- Regulatory influence of α-Pinene on MATN3 expression in hepatocellular carcinoma: Extending to pan-cancer analysis.PloS one · 2025Article
- Article
- A novel M2-like tumor associated macrophages-related gene signature for predicting the prognosis and immunotherapy efficacy in gastric cancer.Discover oncology · 2024Article
- Molecular subtype construction and prognosis model for stomach adenocarcinoma characterized by metabolism-related genes.Heliyon · 2024Article
- The homeoprotein HOXB2 limits triple-negative breast carcinogenesis via extracellular matrix remodeling.International journal of biological sciences · 2024Article
- Article
- Identification and validation of a novel prognostic model for gastric cancer based on m7G-related genes.Translational cancer research · 2023Article
- Transcriptome sequencing and miRNA-mRNA network construction in exosome of macrophage M2 in stomach adenocarcinoma.World journal of surgical oncology · 2023Article
- Review
- An Immunity-Associated lncRNA Signature for Predicting Prognosis in Gastric Adenocarcinoma.Journal of healthcare engineering · 2022Article
- Mutation-Derived Long Noncoding RNA Signature Predicts Survival in Lung Adenocarcinoma.Frontiers in oncology · 2022Article
- Inflammation-Related Genes Serve as Prognostic Biomarkers and Involve in Immunosuppressive Microenvironment to Promote Gastric Cancer Progression.Frontiers in medicine · 2022Article
- Molecular Typing of Gastric Cancer Based on Invasion-Related Genes and Prognosis-Related Features.Frontiers in oncology · 2022Article
- Constructing a novel gene signature derived from oxidative stress specific subtypes for predicting survival in stomach adenocarcinoma.Frontiers in immunology · 2022Article
- A nine-consensus-prognostic -gene-based prognostic signature, recognizing the dichotomized subgroups of gastric cancer patients with different clinical outcomes and therapeutic strategies.Frontiers in genetics · 2022Article
- Hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta gene as a tumour suppressor in stomach adenocarcinoma.Frontiers in oncology · 2022Article
- Identification of lncRNA-associated competing endogenous RNA networks for occurrence and prognosis of gastric carcinoma.Journal of clinical laboratory analysis · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND The aim of this study was to investigate the expression level of martrilin-3 (MATN3) in patients with gastric adenocarcinoma (GAC) and to investigate the prognostic significance of MATN3. MATERIAL AND METHODS Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) data were used to predict the expression and prognostic value of MATN3 mRNA in GAC patients. Seventy-six GAC patients had GAC tissue samples and paired adjacent normal tissue samples collected retrospectively to examine the MATN3 protein expression level by immunohistochemical staining. Furthermore, Kaplan-Meier univariate and Cox multivariate analyses were used to verify the correlation between MATN3 expression and clinicopathological parameters of GAC patients and the prognostic significance of MATN3. RESULTS The GEO and TCGA data predicted that MATN3 mRNA levels were significantly higher in GAC tissue compared to normal tissue (all p<0.05). Further survival analyses showed that GAC patients with high mRNA expression of MATN3 had significantly lower disease-free survival (DFS) and overall survival (OS) time than those with low mRNA expression of MATN3 (all p<0.05). Subsequent immunohistochemical staining results confirmed that the MATN3 protein levels in GAC tissues were highly expressed (p=0.000) compared to normal tissues. In addition, GAC patients with high protein expression of MATN3 had remarkably decreased OS compared to patients with low protein expression of MATN3 (p=0.000). Univariate and multivariate survival analyses revealed that MATN3 high expression could be used as an independent predictor of poor prognosis in GAC patients (all p=0.000). CONCLUSIONS This study confirmed that MATN3 protein was highly expressed in GAC patients, and MATN3 overexpression could be used as an independent predictor of poor prognosis in GAC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.